Equities research analysts at StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK – Get Free Report) in a note issued to investors on Monday. The firm set a “sell” rating on the medical research company’s stock.
Check-Cap Price Performance
Check-Cap stock opened at $2.26 on Monday. The stock has a market capitalization of $13.22 million, a price-to-earnings ratio of -0.75 and a beta of 0.28. Check-Cap has a 1-year low of $1.27 and a 1-year high of $4.63. The business has a fifty day moving average price of $2.24 and a 200-day moving average price of $2.65.
Institutional Trading of Check-Cap
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CHEK. Virtu Financial LLC lifted its holdings in shares of Check-Cap by 363.4% in the 2nd quarter. Virtu Financial LLC now owns 224,696 shares of the medical research company’s stock valued at $69,000 after buying an additional 176,207 shares during the period. Sabby Management LLC acquired a new position in shares of Check-Cap in the 1st quarter valued at about $91,000. Citadel Advisors LLC lifted its holdings in shares of Check-Cap by 51.2% in the 3rd quarter. Citadel Advisors LLC now owns 141,319 shares of the medical research company’s stock valued at $41,000 after buying an additional 47,868 shares during the period. Susquehanna International Group LLP acquired a new position in shares of Check-Cap in the 1st quarter valued at about $57,000. Finally, Nantahala Capital Management LLC acquired a new position in shares of Check-Cap in the 4th quarter valued at about $69,000. Institutional investors and hedge funds own 1.07% of the company’s stock.
About Check-Cap
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.
Further Reading
- Five stocks we like better than Check-Cap
- How to Invest in Small Cap Stocks
- 5 Trends You Need to Know This Quarter
- Conference Calls and Individual Investors
- MarketBeat Week in Review – 4/8 – 4/12
- How to Use the MarketBeat Stock Split Calculator
- You Can Follow BlackRock’s Market View for Your Money
Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with MarketBeat.com's FREE daily email newsletter.